Alpha Cognition Inc (ACOG): Price to Sales
Alpha Cognition management is focused on developing Alzheimer's disease therapies, which is reflected in the P/S volatility on the current GURU.Markets platform chart, where the value 9.30 serves as the baseline indicator. The company attracts biochemists through academic freedom and stock options, while its environmental strategy relies on laboratory safety and digitalization, establishing the foundation for future medical breakthroughs.
Alpha Cognition (ACOG) - metric breakdowns and financial figures
- market price and analyst price targets:
- stock exchange capitalization data:
- shareholders' equity book value data:
- debt obligations and liquidity statistics:
Total Debt to Capital Coefficient Alpha Cognition|ACOG - Long-Term Debt to Equity Ratio|Short-Term Loans to Capital Ratio alphacognition.com|ACOG - Company Aggregate Debts|Debts to Net Assets Alpha Cognition Corp|ACOG - Company Long-Term Debt|Short-Term Debt Alpha Cognition|Immediate Liquidity Ratio alphacognition.com
- earnings and market multiples details:
ACOG - Net Profit|Projected Future Earnings Alpha Cognition|ACOG - P/E Multiple|Projected Price to Earnings alphacognition.com|ACOG - Price/Earnings to Growth Ratio|Company Value to EBITDA Alpha Cognition Corp|ACOG - Operating profit EBITDA|Net earnings per share for the trailing year Alpha Cognition|ACOG - Earnings per share for the last twelve months|Year-over-year earnings per share growth for the last 12 months alphacognition.com|ACOG - Earnings growth in current year|Expected net earnings per share growth next year Alpha Cognition
- total revenue and sales volume data:
General company analysis:ACOG, Alpha Cognition Inc
For Alpha Cognition (ACOG), which invests in upgrading measuring instruments and clinical trials for Alzheimer's drugs, monitoring the company's P/S ratio allows for an assessment of the business's market value relative to its annual sales. This ratio, illustrated on the chart, compares market capitalization with revenue, helping investors identify asset overvaluation or confirm the issuer's leadership by comparing current values with the historical trend.
Competitors of Alpha Cognition
Market Cap to Revenue biogen.com BIIB|Price-to-Revenue Ratio Neurocrine Biosciences, Inc. NBIX|Regencell Bioscience Ltd (RGC) - Price to Sales|Axsome Therapeutics Inc - P/S Multiple|Price-to-Revenue Multiple ACADIA Corp (ACAD)|Xenon Pharmaceuticals (XENE) - Price-to-Revenue Ratio|Market Cap to Revenue Ratio VKTX|SUPN (Supernus) - P/S Multiple|Catalyst Pharma (CPRX) - Price-to-Revenue Coefficient|Market Cap to Revenue DNLI (Denali Therapeutics Inc)|Market Cap to Sales Volume HRMY|P/S Multiple BHVN (Biohaven Ltd.)|Price-to-Revenue Coefficient amylyx.com (AMLX)|TRVI - Price-to-Revenue Ratio|Price to Sales Praxis Precision Medicines Inc|Anavex Corp (AVXL) - Price-to-Revenue Ratio|Market Cap to Revenue Ratio CBLL|PRTA (Prothena Biosciences) - P/S Multiple|P/S Multiple Alector Therapeutics|P/S Multiple ANNX|Market Cap to Revenue omeros.com OMER|Price-to-Revenue Ratio Neurogene Corp NGNE|AC Immune Inc (ACIU) - Price to Sales|Voyager Therapeutics - P/S Multiple|Price-to-Revenue Multiple neumoratx.com (NMRA)|Scilex (SCLX) - Price-to-Revenue Ratio|Market Cap to Revenue Ratio TVGN|CGTX (Cognition Therapeutics, Inc.) - P/S Multiple|Price to Sales Inhibikase Pharma IKT|Market Cap to Revenue SAVA (Cassava Sciences, Inc.)|P/S Multiple assertiotx.com (ASRT)|Price-to-Revenue Ratio Coya Therapeutics COYA|Market Capitalization-to-Revenue Ratio VTGN|OVID - Price-to-Revenue Ratio|Price to Sales Acumen Pharmaceuticals, Inc|CRVO: P/S Multiple|Alterity Therapeutics Limited (ATHE) - P/S Multiple|Price-to-Revenue Ratio Clene Inc|Price-to-Revenue Ratio PEPG|Price-to-Revenue Ratio Jupiter Neurosciences (JUNS)|RLMD: Price-to-Sales Ratio|P/S Multiple ANVS (Annovis Bio, Inc.)|Market Capitalization-to-Revenue Ratio GRCE|Firefly Neuroscience - P/S Multiple|KLTO - P/S Multiple|NRSN (neurosense-tx.com) - Market Cap to Revenue|Reviva Pharmaceuticals, Inc. - Market Capitalization-to-Revenue Ratio|MTVA (MetaVia Inc.) - P/S Multiple|Market Cap to Revenue neuraxis.com (NRXS)|Price-to-Revenue Ratio Helius Medical (HSDT)|PASG - Price to Sales|P/S Multiple NEUP (Neuphoria Therapeutics)|Price-to-Revenue Multiple Minerva|ATHA - Price-to-Revenue Ratio|ADXN (addextherapeutics.com) - Market Cap to Revenue Ratio|ALZN: P/S Multiple|CYCN - Price-to-Revenue Coefficient|Market Cap to Revenue PTIX|KTTA (Pasithea) - Market Cap to Sales Volume|P/S Multiple CRGT|Price-to-Revenue Coefficient avenuetx.com|Price-to-Revenue Ratio BrainStorm Cell Therapeutics BCLI|Cara Therapeutics Inc. (CARA) - Price to Sales|CHRO - Price-to-Revenue Ratio|ELYM (Eliem Therapeutics) - Market Cap to Revenue Ratio|ITCI: P/S Multiple|longboardpharma.com (LBPH) - P/S Multiple|MRNS (Marinus Pharmaceuticals, Inc.) - P/S Multiple|Market Cap to Revenue NKGen Biotech Inc (NKGN)|Price-to-Revenue Ratio NeuroBo (NRBO)|SAGE - Price to Sales|P/S Multiple SNPX (Synaptogenix, Inc.)|Price-to-Revenue Multiple trevena.com|VIGL - Price-to-Revenue Ratio|WENA (anewmeds.com) - Market Cap to Revenue Ratio|CERE: P/S Multiple
